Randomized controlled trial to evaluate the effect of prophylactic antibiotic administration for patients in totally implantable central venous port

Randomized controlled trial to evaluate the effect of prophylactic antibiotic administration for patients in totally implantable central venous port - Randomized controlled trial on prophylactic antibiotic administration in totally implantable central venous port

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031345

Enrollment

140

Registered

2018-02-17

Start date

2018-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Case of totally implantable central venous port

Interventions

Administration of 1g of cefazolin before and after surgery Omission of prophylactic antibiotics administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with elective totally implantable central venous port 2) No previous chemotherapy or radiation 3) Fulfil all following conditions WBC > 3,000/mm3 Plt > 100,000/mm3 AST < 100 IU/L ALT < 100IU/L T.Bil < 2.0 g/dl Cre < 1.5mg/dl 4) written informed consent

Exclusion criteria

Exclusion criteria: 1) Having active infectious disease 2) With uncontrolled diabetes mellitus 3) With myelosuppression due to immunodeficiency or chemotherapy history 4) With short bowel syndrome 5) With allergy to cephalosporin 6) Patient judged inappropriate by the attending physician

Design outcomes

Primary

Measure	Time frame
Incidence of surgical site infection within 30 days after totally implantable central venous port	—

Secondary

Measure	Time frame
Incidence of totally infectious complications within 30 days after totally implantable central venous port	—

Countries

Japan

Contacts

Public ContactRyo Tanaka

Osaka Medical College General and Gastroenterological Surgery

sur148@osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026